BETA
Nevada-based developer investigating EEG-guided electrical neuromodulation for chronic pain.
Biocurrent is a privately held medical-device developer based in Henderson, Nevada. Founded by Andrew Blount in 2020, it is researching a system that uses scalp EEG signals and software to adjust electrical stimulation delivered through skin electrodes.
The company reports a 333-participant, single-site pain study in Puerto Vallarta, Mexico, comparing its system with active interferential current therapy. Its September 2026 manuscript summary describes immediate pain-score differences favoring Biocurrent. The unregistered study has no follow-up beyond participants’ final sessions, and peer-reviewed publication has not been established.
The device remains investigational and unavailable for commercial sale. No FDA clearance or approval was identified. Current materials emphasize chronic-pain research; earlier founder statements about Alzheimer’s research and related-site claims of a pending 510(k) require confirmation.
Biocurrent is developing an EEG-guided electrical stimulation system for chronic-pain research. No FDA clearance or approval has been identified; the company also states it has neither. The applicable FDA classification and submission pathway are not confirmed. [14][1][4][7][8][15]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [17][18]
Latest recorded source review: 2026-10-20.
No marketed products established. The device remains in development.
Biocurrent’s investigational platform combines EEG sensing, software-controlled stimulation and surface electrodes. V6 is shown as current development hardware, without confirmation that it matches the reported study configuration. Earlier founder reports of Alzheimer’s research remain unconfirmed as a current separate program. [14][1][5]
Closed-loop research platform combining EEG sensing, AI-assisted control and transcutaneous alternating-current stimulation. V6 is current development hardware; study-device equivalence is unconfirmed. [14][1][2]
Investigational / in developmentInvestigational; not available for commercial sale
September 24 draft summary reports 333 participants and 817 sessions, with 228 assigned to Biocurrent and 105 to active ICT. The reported baseline-adjusted immediate pain-score difference was 2.03 points on a 0–10 scale. No inert sham, longer-term follow-up or public trial registration was reported; attendance differed between arms. This is sponsor-reported research, not established clinical effectiveness or peer-reviewed publication. [1][2]
Company materials date Andrew Blount’s founding of Biocurrent to 2020. [14]
Accessed 10/20/2026